Jun 2026 (Q2 FY26) — Aug 6, 2026
Verrica Pharmaceuticals Q2 FY26 — Strong YCAMP Growth and Extended Cash Runway
Read the full callVerrica Pharmaceuticals (VRCA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Verrica Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 5.9 | −53.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -223.4 | −235.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -13.2 | −6547.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.44 −4.44% · −$0.16
Performance −17.1% 1Y
1Y: $4.15 on 17 Oct 2025 → $3.44. High $9.1 (28 Nov 2025), low $3.28 (4 Nov 2025).
- Previous close
- $3.6
- 52-week range
- $3.28 – $9.1
- One year
- −23.21%
Overview
- Symbol
- VRCA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Verrica Pharmaceuticals earnings calls (VRCA)
Financials
What the filings say
Net profit, year on year: −6548% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | -2 | 0 | 3 | 13 | 14 | 5 | 5 | 6 |
| Operating profit | -21 | -11 | -8 | 2 | 2 | -7 | -10 | -13 |
| Operating margin | 1162.5% | −3316.9% | −236.4% | 11.9% | 11.3% | −141.2% | −193.4% | −223.4% |
| Other income | -2 | -5 | -2 | -1 | -2 | -1 | 0 | -0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 |
| Net profit | -23 | -16 | -10 | 0 | -0 | -8 | -10 | -13 |
| EPS ($ per share) | -4.88 | — | -1.03 | 0.02 | -0.03 | — | -0.45 | -0.62 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -33 | -61 | -104 | -139 | -163 | -230 | -307 | -325 |
| Total liabilities | 2 | 3 | 41 | 48 | 5 | 62 | 64 | 22 |
| Fixed assets | 0 | 2 | 3 | 4 | 4 | 1 | 1 | 0 |
| Total assets | 92 | 68 | 74 | 80 | 45 | 82 | 54 | 47 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18 | -27 | -30 | -28 | -19 | -39 | -61 | -18 |
| Cash from investing | -80 | 26 | -4 | -1 | 54 | -0 | -0 | 0 |
| Cash from financing | 99 | 0 | 35 | 34 | -17 | 74 | 38 | 1 |
| Net cash flow | 2 | -1 | 1 | 5 | 19 | 35 | -23 | -16 |
| Capital expenditure | -1 | -1 | -1 | -1 | -0 | -0 | -0 | 0 |
| Free cash flow | -19 | -28 | -32 | -28 | -19 | -39 | -61 | -18 |
Insider filings
13 filings between Nov 25, 2025 and Aug 18, 2026.
Open market
decisions to buy or sellPurchases
$18.18M
12 purchases by 5 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Manning Paul B | $17.51M | — | Nov 25, 2025 |
| Rieger Jayson | $525.9K | — | Aug 17, 2026 |
| Zawitz David | $72.3K | — | Aug 17, 2026 |
| Rosenberg Noah L. | $40.6K | — | Aug 18, 2026 |
| Kirby John J. | $39.7K | — | Aug 18, 2026 |
Latest filings (31)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Rosenberg Noah L. CMO | Purchase | 2,030 | $10.0K |
| Aug 18, 2026 | Kirby John J. Interim CFO | Purchase | 5,000 | $24.6K |
| Aug 17, 2026 | Zawitz David Chief Operating Officer | Purchase | 6,000 | $29.9K |
| Aug 17, 2026 | Rosenberg Noah L. CMO | Purchase | 4,200 | $20.6K |
| Aug 17, 2026 | Rieger Jayson CEO and President | Purchase | 5,000 | $24.6K |
| Aug 14, 2026 | Rieger Jayson CEO and President | Purchase | 20,000 | $101.2K |
| Dec 23, 2025 | Kirby John J. Interim CFO | Award | 10,000 | $0 |
| Nov 25, 2025 | Manning Paul B Director | Purchase | 1,375,380 | $5.84M |
| Nov 25, 2025 | Manning Paul B Director | Purchase | 2,750,762 | $11.67M |
| Nov 25, 2025 | Kirby John J. Interim CFO | Purchase | 3,536 | $15.0K |
| Nov 25, 2025 | Rosenberg Noah L. CMO | Purchase | 2,357 | $10.0K |
| Nov 25, 2025 | Rieger Jayson CEO and President | Purchase | 94,311 | $400.1K |
| Nov 25, 2025 | Zawitz David Chief Operating Officer | Purchase | 10,000 | $42.4K |
| Mar 17, 2025 | Hayes Christopher G. CHIEF LEGAL OFFICER | Sale | 4,315 | $2.8K |
| Nov 26, 2024 | Manning Paul B Director | Gift | 450,000 | $0 |
| Nov 26, 2024 | Rieger Jayson CEO and President | Gift | 50,000 | $0 |
| Nov 26, 2024 | Stalfort John A III Director | Gift | 50,000 | $0 |
| Nov 22, 2024 | Rieger Jayson CEO and President | Purchase | 280,898 | — |
| Nov 22, 2024 | Stalfort John A III Director | Purchase | 1,123,595 | — |
| Nov 22, 2024 | Manning Paul B Director | Purchase | 18,426,966 | — |
| Nov 22, 2024 | Manning Paul B Director | Purchase | 4,494,382 | — |
| Nov 6, 2024 | Kirby John J. Interim CFO | Award | 54,267 | $0 |
| Sep 19, 2024 | Manning Paul B Director | Gift | 891,870 | $0 |
| Sep 19, 2024 | Manning Paul B Director | Gift | 2,675,611 | $0 |
| Sep 19, 2024 | Manning Paul B Director | Gift | 891,870 | $0 |
| Sep 19, 2024 | Manning Paul B Director | Gift | 891,870 | $0 |
| Aug 24, 2023 | White Ted PRESIDENT AND CEO | Award | 150,000 | $0 |
| Aug 24, 2023 | Bonaccorso Joe CHIEF COMMERCIAL OFFICER | Award | 125,000 | $0 |
| Aug 24, 2023 | Goldenberg Gary Chief Medical Officer | Award | 50,000 | $0 |
| Aug 24, 2023 | Kohler Terry CHIEF FINANCIAL OFFICER | Award | 125,000 | $0 |
| Aug 24, 2023 | Hayes Christopher G. CHIEF LEGAL OFFICER | Award | 150,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Verrica Pharmaceuticals Inc.
Free account. Everything above stays public.
Write why you follow Verrica Pharmaceuticals Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading